Oramed Pharmaceuticals to Join Russell 2000 and 3000 Indexes on June 29
ORMP•Oramed Pharmaceuticals Inc. will join the Russell 2000 and Russell 3000 Indexes effective at the market open on June 29 after the June 26 semi-annual reconstitution based on market caps as of April 30. Inclusion places Oramed in benchmarks overseeing $12.2 trillion in U.S. index assets.
1. Russell Reconstitution and Timetable
The semi-annual Russell index reconstitution ranks the 4,000 largest U.S. stocks by total market capitalization as of April 30, 2026. Oramed Pharmaceuticals will be added to the broad-market Russell 3000 and small-cap Russell 2000 after markets close on June 26, becoming effective at the June 29 open.
2. Implications for Stock Demand
Approximately $12.2 trillion in U.S. assets are benchmarked to Russell indexes. Oramed’s inclusion is likely to trigger purchase orders from index funds and ETFs that track the Russell 2000 and 3000 benchmarks, potentially boosting share liquidity and demand.
3. Oramed Pharmaceuticals Business Overview
Oramed Pharmaceuticals Inc. deploys capital across biomedical and broader investments, leveraging regulatory expertise and industry relationships to build and actively support a diversified portfolio of clinical, commercial and royalty-generating assets.
